Medincell Shares Plunge After FY2026 Results Show Wider Loss, Trial Delay
Medincell stock tumbled after the company reported fiscal 2026 results that featured a larger net loss, falling headline income and a sharp rise in operating loss driven by stepped-up R&D and commercial investment. The slide was intensified by news that an AbbVie-partnered clinical program has been pushed into 2027, removing an expected near-term c…